english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Revision of European pharmaceutical legislation

Safety signals: why bother?

Abemaciclib (Verzenios°), palbociclib (Ibrance°) and ribociclib (Kisqali°) added to an aromatase inhibitor in certain breast cancers

When the cause of a disorder is not immediately obvious: could a drug be responsible?

Prescribing cascades: recognise them and take corrective action

When to take a safety signal into account: Prescrire's experience

Defending the right to compensation for the victims of drug-induced harms

Patient characteristics

Nirsevimab (Beyfortus°) to prevent RSV infection in infants

Negative post-marketing trials: often ignored

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90